US-based Light Horse Therapeutics Inc., a small molecule drug developer that recently emerged from the Inception Incubator with a USD 62 million Series A funding, has struck a strategic partnership with Swiss pharmaceutical giant Novartis (NYSE: NVS). The collaboration aims to identify and develop potentially first-in-class therapeutics using Light Horse’s innovative platform. This partnership underscores the potential of Light Horse’s technology in advancing novel treatments.
Deal Terms and Financials
Under the terms of the deal, Light Horse will receive an upfront payment of USD 25 million from Novartis. Additionally, Light Horse is eligible for up to USD 1 billion in further research, development, and sales milestones, followed by royalties. This significant financial commitment from Novartis highlights the confidence in Light Horse’s platform and its potential to deliver breakthrough therapies.
Investment and Support
Light Horse’s founding investor, Versant Ventures, led the Series A financing round, which was also supported by Mubadala Capital and three strategic investors. This strong financial backing has positioned Light Horse to accelerate its drug development programs and leverage its platform to create innovative therapeutics.
Future Prospects
The partnership with Novartis is a major milestone for Light Horse Therapeutics, providing the company with the resources and expertise to advance its pipeline of potentially first-in-class therapeutics. By collaborating with a global leader like Novartis, Light Horse aims to bring novel treatments to patients in need, addressing significant unmet medical needs in various therapeutic areas.
